Počet záznamů: 1
Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy
- 1.
SYSNO ASEP 0384103 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy Tvůrce(i) Talelli, M. (NL)
Oliveira, S. (NL)
Rijcken, C. J. F. (NL)
Pieters, E. H. E. (NL)
Etrych, Tomáš (UMCH-V) RID, ORCID
Ulbrich, Karel (UMCH-V) RID
van Nostrum, R. C. F. (NL)
Storm, G. (NL)
Hennink, W. E. (NL)
Lammers, T. (NL)Zdroj.dok. Biomaterials. - : Elsevier - ISSN 0142-9612
Roč. 34, č. 4 (2013), s. 1255-1260Poč.str. 6 s. Jazyk dok. eng - angličtina Země vyd. GB - Velká Británie Klíč. slova polymeric micelle ; doxorubicin ; active targeting Vědní obor RIV CD - Makromolekulární chemie CEP IAA400500806 GA AV ČR - Akademie věd GAP301/11/0325 GA ČR - Grantová agentura ČR CEZ AV0Z40500505 - UMCH-V (2005-2011) UT WOS 000313155800038 DOI https://doi.org/10.1016/j.biomaterials.2012.09.064 Anotace Various different passively and actively targeted nanomedicines have been designed and evaluated over the years, in particular for the treatment of cancer. Reasoning that the potential of ligand-modified nanomedicines can be substantially improved if intrinsically active targeting moieties are used, we have here set out to assess the in vivo efficacy of nanobody-modified core-crosslinked polymeric micelles containing covalently entrapped doxorubicin. Nanobody-modified polymeric micelles were found to inhibit tumor growth even in the absence of a drug, and nanobody-modified micelles containing doxorubicin were significantly more effective than nanobody-free micelles containing doxorubicin. Based on these findings, we propose that the combination of two therapeutic strategies within one nanomedicine formulation, i.e. the intrinsic pharmacological activity of ligand-modified carrier materials with the cytostatic activity of the incorporated chemotherapeutic agents, is a highly promising approach for improving the efficacy of tumor-targeted combination therapy. Pracoviště Ústav makromolekulární chemie Kontakt Eva Čechová, cechova@imc.cas.cz ; Tel.: 296 809 358 Rok sběru 2013
Počet záznamů: 1